Caffeine Intake and Dementia: Can Lewy Bodies Explain the Link?
Researchers sought to investigate the associations between habitual caffeine intake, incident cognitive impairment, and neuropathology.
Lewy Body Dementia
GBA Variants Impact Cognitive Status in Amyotrophic Lateral Sclerosis
Researchers sought to determine the effect GBA variants have on cognitive status in patients with amyotrophic lateral sclerosis.
Could Lyme Disease Cause Alzheimer Disease or Lewy Body Dementia?
A team of researchers investigated whether credible evidence supporting a causal relationship between Lyme disease and Alzheimer disease or Lewy body dementia exists.
Using Neuropsychological Profiles to Differentiate MCI Progression to Alzheimer Disease vs Lewy Body Dementia
A researcher assessed the predictive power of neuropsychologic features in distinguishing the progression to Alzheimer disease vs Lewy body dementia in patients with mild cognitive impairment.
Assessing the Link Between Alzheimer Disease Co-Pathology and Neuropsychiatric Symptoms in Lewy Body Dementia
Researchers explored the association between Alzheimer disease co-pathology and the presence and severity of neuropsychiatric symptoms in Lewy body dementia.
Nelotanserin May Be Ineffective for Motor, Vocal Manifestations of RBD in Lewy Body and PD Dementia
Using systematic video analysis, researchers assessed the efficacy of nelotanserin for symptomatic treatment of REM sleep behavior disorder in patients with dementia.
Lewy Body Dementia With AD Copathology Linked to Impaired Language Performance
Patients with Lewy body dementia with likely AD-type copathology may have impaired language compared to those without such copathology.
Neflamapimod Gets Fast Track Status for Dementia With Lewy Bodies
The FDA has granted Fast Track designation to neflamapimod (EIP Pharma) for the treatment of dementia with Lewy bodies (DLB).
Leveraging Neuroimaging for the Diagnosis of Psychiatric and Neurodegenerative Diseases
A number of psychiatric and neurodegenerative diseases are associated with abnormal imaging findings, which can help psychiatrists reach a diagnosis.
Pimavanserin and Quetiapine Comparable for Psychosis in Parkinson Disease
There were no significant differences between pimavanserin and quetiapine in time to discontinuation, mortality, or improvement in psychosis in patients with Parkinson disease and Lewy body dementia.
- Loading...
Loading...
Next post in AAN 2019 Conference
Loading... 
Loading...